Full Text View
Tabular View
No Study Results Posted
Related Studies
Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers
This study is currently recruiting participants.
Verified by University Hospital, Angers, March 2007
First Received: September 8, 2005   Last Updated: March 16, 2007   History of Changes
Sponsor: University Hospital, Angers
Information provided by: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT00152724
  Purpose

Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin. The purpose of the study is to investigate the physiological response of the cutaneous microcirculation to physical, thermal, mechanical or chemical stimulations.


Condition Intervention Phase
Healthy Volunteers
Device: pressure strain system, iontophoresis
Drug: scopolamin
Drug: emla
Drug: capsaicin
Drug: aspirin
Drug: clopidogrel
Drug: celecoxib
Drug: indomethacin
Drug: acetylcholine
Drug: sodium nitroprusside
Drug: brethyllium
Device: general and local heating
Phase IV

Study Type: Interventional
Study Design: Diagnostic, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: Etude de la Reserve Vasomotrice Microcirculatoire cutanée

Resource links provided by NLM:


Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:
  • Amplitude of the vasomotor response to stimuli

Secondary Outcome Measures:
  • Kinetics of the vasomotor response to stimuli

Estimated Enrollment: 85
Study Start Date: January 1996
Estimated Study Completion Date: January 2008
Detailed Description:

This study has investigated various aspects of the physiology of the microcirculation in the past years and is still recruiting under parallel protocols of physiological investigations of the neurovascular control of the cutaneous microcirculation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers with no clinical signs of, or risk factors for, vascular disease

Exclusion Criteria:

  • Smokers, Pregnancy, Allergy,
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00152724

Contacts
Contact: Pierre ABRAHAM, MD, PhD (0)2-41-35-46-17 ext 33 piabraham@chu-angers.fr

Locations
France
Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers Recruiting
Angers, France, 49033
Contact: Pierre ABRAHAM, MD, PhD     (0)2-41-35-46-17 ext 33     piabraham@chu-angers.fr    
Sponsors and Collaborators
University Hospital, Angers
Investigators
Principal Investigator: Jean Louis SAUMET, MD - PhD University Hospital, Angers
  More Information

Publications:
Tartas M, Durand S, Koitka A, Bouye P, Saumet JL, Abraham P. Anodal current intensities above 40 microA interfere with current-induced axon-reflex vasodilatation in human skin. J Vasc Res. 2004 May-Jun;41(3):261-7. Epub 2004 May 19.
Durand S, Fromy B, Humeau A, Sigaudo-Roussel D, Saumet JL, Abraham P. Break excitation alone does not explain the delay and amplitude of anodal current-induced vasodilatation in human skin. J Physiol. 2002 Jul 15;542(Pt 2):549-57.
Tartas M, Bouye P, Koitka A, Durand S, Gallois Y, Saumet JL, Abraham P. Early vasodilator response to anodal current application in human is not impaired by cyclooxygenase-2 blockade. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1668-73. Epub 2004 Nov 24.
Durand S, Tartas M, Bouye P, Koitka A, Saumet JL, Abraham P. Prostaglandins participate in the late phase of the vascular response to acetylcholine iontophoresis in humans. J Physiol. 2004 Dec 15;561(Pt 3):811-9. Epub 2004 Oct 21.
Durand S, Fromy B, Tartas M, Jardel A, Saumet JL, Abraham P. Prolonged aspirin inhibition of anodal vasodilation is not due to the trafficking delay of neural mediators. Am J Physiol Regul Integr Comp Physiol. 2003 Jul;285(1):R155-61.
Durand S, Fromy B, Koitka A, Tartas M, Saumet JL, Abraham P. Oral single high-dose aspirin results in a long-lived inhibition of anodal current-induced vasodilatation. Br J Pharmacol. 2002 Oct;137(3):384-90.
Durand S, Fromy B, Bouye P, Saumet JL, Abraham P. Vasodilatation in response to repeated anodal current application in the human skin relies on aspirin-sensitive mechanisms. J Physiol. 2002 Apr 1;540(Pt 1):261-9.

Study ID Numbers: CP96-04
Study First Received: September 8, 2005
Last Updated: March 16, 2007
ClinicalTrials.gov Identifier: NCT00152724     History of Changes
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Angers:
Physiology
Microcirculation
Laser-Doppler Flowmetry

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Vasodilator Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hematologic Agents
Physiological Effects of Drugs
Reproductive Control Agents
Cholinergic Agents
Gout Suppressants
Nitric Oxide Donors
Tocolytic Agents
Sensory System Agents
Therapeutic Uses
Indomethacin
Antipruritics
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Dermatologic Agents
Celecoxib
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Capsaicin
Pharmacologic Actions
Analgesics, Non-Narcotic
Clopidogrel
Nitroprusside
Platelet Aggregation Inhibitors
Acetylcholine

ClinicalTrials.gov processed this record on February 08, 2010